Taken together, our data demonstrate that HCC may behave according to this novel prediction model, and also suggest that type I tumors, that is tumors with an ongoing antitumor immune response (high PD-L1 and high TIL count), may be the ones to benefit from PD-L1 or PD-1 blockade. This evidence concerns the gene CD274 and hepatocellular carcinoma.